Stay updated with breaking news from Jeffrey Eisele. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 10,590,000 shares, a growth of 5.3% from the February 29th total of 10,060,000 shares. Based on an average trading volume of 1,580,000 shares, […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to […]
Teacher Retirement System of Texas grew its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 5.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,099 shares of the company’s stock after purchasing an additional 1,203 shares during the quarter. […]
WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
Apellis Pharmaceuticals, Inc. (APLS) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a negative opinion for Pegcetacoplan for geographic atrophy or GA.